What lies ahead for the future of pharma? Dennis van Rooji gives his view.

With US courts consistently ruling in favor of the PrEP drug manufacture, the CDC and DHHS have had no choice but to be humble.

Trump withdraws the US from the WHO and pharma stakeholders call for changes to price negotiation program

The industry is under pressure to reduce the risks of nitrosamines in both in-development and on-market drug products.

Accelerating the progress of cell and gene therapies with decentralized trials and other innovative approaches.

Proprietary nanovesicles technology has caught the eye of Eli Lilly. We find out why.

AI helps make preclinical decisions faster, but stakeholders remain cautious. We asked an expert from Elsevier for their views on the challenges.

Understanding the role of spatially offset Raman spectroscopy in identifying raw materials, counterfeit medicines, and more.

AI is not just for the drug development phase of pharmaceutical manufacturing. Now is the time for the business side to leverage it.

The trends and challenges in oral solid dosage formulations contribute to greater stability for drugs used by patients worldwide.